New imaging tracks cancer drug in body
NCT ID NCT05638334
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study used PET scans to track where a new antibody drug (S095012) goes in the body and in tumors of people with advanced solid cancers. Only 3 participants were enrolled before the study was stopped early. The goal was to understand how the drug spreads and targets tumors, not to test if it works as a treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
S095012 (a bispecific antibody targeting PD-L1 and 4-1BB) and a radioactive tracer (89Zr-S095012)
What this could lead to
If successful, this imaging approach could help doctors see which patients might benefit from S095012 treatment.
What could go wrong
This was a very small, early-phase study (only 3 participants) that was terminated early, so results are limited and may not apply broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UMC Gronningen Oncologie
Groningen, 9713 AZ, Netherlands